GlassScriptPhysician profile
Jack Goldshlack
NPI 1316991458
$800.12
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $128.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $188.55 | 2019-2020 | |
| Philips North America LLC | $83.92 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $83.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.59 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.21 | 2019-2020 | |
| Grifols USA, LLC | $53.11 | 2019-2020 | |
| Mylan Specialty L.P. | $33.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.15 | 2019 | |
| Merck Sharp & Dohme LLC | $28.07 | 2019 | |
| Jazz Pharmaceuticals INC. | $26.55 | 2019 | |
| Horizon Therapeutics Plc | $25.43 | 2019 | |
| Advanced Respiratory, INC | $19.93 | 2019 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Optinose US, INC. | $14.52 | 2020 | |
| Mallinckrodt Hospital Products INC. | $12.93 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $12.86 | 2019 | |
| Circassia INC. | $11.95 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Goldshlack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.